Clinical Trials Logo

Clinical Trial Summary

iTRAP is an open-label, multi-centre, dose escalation study of ADI PEG20 in combination with atezolizumab, pemetrexed and carboplatin in patients with advanced non-squamous non-small cell lung carcinoma (NSCLC) - stage IIIB/IV.


Clinical Trial Description

iTRAP is an open-label, multi-centre, dose escalation study of ADI PEG20 in combination with atezolizumab, pemetrexed and carboplatin in patients with advanced non-squamous NSCLC (stage IIIB/IV). Patients will initially receive 4 cycles of ADI PEG20 in combination with atezolizumab, pemetrexed and carboplatin unless there is documented disease progression or unacceptable toxicities. On completion of 4 cycles and in the absence of disease progression requiring other therapeutic interventions, patients may receive additional cycles of ADI PEG20 and/or atezolizumab and/or pemetrexed for up to a maximum of 2 years at the discretion of the treating physician.

Dose escalation will occur using a 3 + 3 design. The trial will start at dose level 1, which represents 100% of the recommended dose of carboplatin (AUC5) and pemetrexed (500mg/m2) when given as a combination, 100% of the atezolizumab recommended dose (1200mg) and 50% of the recommended single agent dose of ADI PEG20 (18mg/m2). ADI PEG20 doses will be increased according to pre-planned dose escalations.

If the maximum tolerated dose (MTD) is reached with the first 6 patients, up to an additional 6 patients will be enrolled at the MTD. The MTD is defined as the dose level below that at which 2/3 or ≥3/6 patients experience a dose limiting toxicity (DLT).

The maximum administered dose (MAD) may also equal the MTD if dose escalation is stopped before two DLTs are observed at a given dose level due to the expectation that higher dose levels would be too toxic to administer to patients or the maximum planned dose level has been achieved.

The MTD will be determined following review of all the relevant toxicity data by the Safety Review Committee (SRC).

If dose level 1 equals the MAD then dose level -1 may be investigated with a 50% reduction in ADI PEG20 (9mg/m2) along with atezolizumab 1200mg, carboplatin AUC5, and pemetrexed 500mg/m2. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03498222
Study type Interventional
Source Queen Mary University of London
Contact Kelly Mousa
Phone 02078828197
Email k.mousa@qmul.ac.uk
Status Not yet recruiting
Phase Phase 1
Start date June 1, 2018
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT02864394 - Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033) Phase 3
Active, not recruiting NCT01953913 - Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation Phase 3
Not yet recruiting NCT03456076 - A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer Phase 3
Recruiting NCT02934360 - TR(ACE) Assay Clinical Specimen Study N/A
Recruiting NCT02926768 - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT02847377 - A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC Early Phase 1
Completed NCT01160744 - A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 2
Active, not recruiting NCT00921310 - Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT01860898 - A Phase I Study of iPS Cell Generation From Patients With COPD N/A
Completed NCT01022671 - Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy Phase 2
Completed NCT00932893 - An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene Phase 3
Active, not recruiting NCT00690963 - Individual Boosting in Non-Small Cell Lung Cancer Using Hypofractionation, Intensity-modulated Radiation Therapy and Respiratory Gating Phase 1/Phase 2
Recruiting NCT00797238 - DNA Repair Genes and Outcomes in Patients With Stage III NSCLC N/A
Completed NCT00531401 - Study of Salirasib to Treat Non-Small Cell Lung Cancer Phase 2
Completed NCT00600587 - Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC) Phase 2
Terminated NCT00558636 - A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) Phase 3
Terminated NCT00539331 - Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients Phase 1
Terminated NCT00535275 - NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy Phase 3
Terminated NCT00532025 - Sorafenib in Resected Non-small Cell Lung Carcinoma Phase 2
Terminated NCT00558922 - A Phase 1-2 XIAP Antisense AEG35156 With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer Phase 1/Phase 2